Corrigendum: Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma

Yixing Gao; Bao Liu; Lan Feng; Binda Sun; Shu He; Yidong Yang; Gang Wu; Guoji E; Chang Liu; Yuqi Gao; Erlong Zhang; Bo Zhu

doi:10.3389/fonc.2020.00644

Corrigendum: Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma

Front Oncol. 2020 Apr 28:10:644. doi: 10.3389/fonc.2020.00644. eCollection 2020.

Authors

Yixing Gao¹, Bao Liu^{2

3}, Lan Feng^{2

3}, Binda Sun^{2

3}, Shu He^{2

3}, Yidong Yang^{2

3}, Gang Wu^{2

3}, Guoji E^{2

3}, Chang Liu^{2

3}, Yuqi Gao^{2

3}, Erlong Zhang^{2

3}, Bo Zhu¹

Affiliations

¹ Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing, China.
² Institute of Medicine and Equipment for High Altitude Region, College of High Altitude Military Medicine, Army Medical University, Chongqing, China.
³ Key Laboratory of High Altitude Medicine, People's Liberation Army, Chongqing, China.

Abstract

[This corrects the article DOI: 10.3389/fonc.2019.00033.].

Keywords: CEBPB; HDAC3; JUN; drug resistance; glioblastoma; hypoxia.

Publication types

Published Erratum